Page 21 - B Cell News Today

Younger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination.

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

News-Medical speaks to Professor Tomohiro Kurosaki about how he has developed a new vaccine approach that could prevent future pandemics.

Researchers opted to use single-cell RNA-seq to observe single cells in detail as they encounter a specific antigen.

Researchers performed a large-scale, double-blind, placebo-controlled phase two trial to assess the efficacy, safety, and immune response elicited from vaccination with MVC-COV1901.

Nine out of 10 patients with systemic lupus erythematosus -; the autoimmune disease also known as SLE -; are females.

A new study published in the journal Nature attempted to investigate memory B cell evolution 5 months after vaccination with mRNA vaccines such as Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) in SARS-CoV-2 naïve individuals. The study explored various aspects of memory B cell antibody response like neutralizing response, affinity, epitope targeting, and neutralizing breadth.

After infection with SARS-CoV-2, where does the immune system store the memory to provide long-term protection against reinfection?

Hope for a future without fear of COVID-19 comes down to circulating antibodies and memory B cells. Unlike circulating antibodies, which peak soon after vaccination or infection only to fade a few months later, memory B cells can stick around to prevent severe disease for decades. And they evolve over time, learning to produce successively more potent "memory antibodies" that are better at neutralizing the virus and more capable of adapting to variants.